View in EDS

Semaglutide-Induced Weight Loss: Consequences for Muscle Mass and Functional Outcomes.

Saved in:
Bibliographic Details
Title: Semaglutide-Induced Weight Loss: Consequences for Muscle Mass and Functional Outcomes.
Authors: Reizer, Barbara1 basia.reizer@gmail.com, Botto, Zofia2 lek.botto@gmail.com, Krystek, Klaudia krystekklaudia@gmail.com, Felisiak, Patrycja3 patfelisiak@gmail.com, Kowalczyk, Dominika kowalczyk.dominika11@gmail.com, Śliwa, Zofia zosia.sliwa@gmail.com, Ślazyk, Dominik Andrzej4 dominik.slazyk98@gmail.com
Source: Journal of Education, Health & Sport. 2026, Vol. 88, p1-17. 17p.
Subject Terms: Semaglutide, Muscle mass, Lean body mass, Appetite disorders, Resistance training, Functional status, Weight loss, Glucagon-like peptide-1 agonists
Abstract: Introduction: Semaglutide (Ozempic) is a long-acting GLP-1 receptor agonist used in the treatment of type 2 diabetes and obesity. Its potent effects on appetite suppression, delayed gastric emptying, and weight reduction are well documented. Increasing scientific attention has focused on its potential influence on lean body mass and skeletal muscle, as emerging evidence suggests that semaglutide-induced weight loss may include clinically relevant reductions in muscle mass. Understanding the extent and significance of these changes is essential for safe long-term therapy. Material and Methods of Research: A literature review was conducted using PubMed, Google Scholar, and Scopus. Clinical trials, observational studies, meta-analyses, and relevant preclinical research published in English between 2018 and 2024 were analyzed. Results: Evidence indicates that semaglutide-induced weight loss consistently leads to reductions in lean mass, typically comprising 20–40% of total weight lost. Mechanisms include caloric deficit, reduced protein intake, appetite suppression, and changes in anabolic signalin. Several studies demonstrated preserved muscle strength or stabilization of lean mass when therapy was combined with adequate protein intake and resistance training. Preclinical findings suggest that part of the lean mass reduction is reversible after treatment discontinuation. Conclusion: Semaglutide affects muscle mass primarily indirectly through appetite suppression and significant weight reduction. While lean mass loss is common, functional muscle decline is not inevitable and may be mitigated through dietary optimization and structured physical activity. Regular monitoring of body composition should be considered during semaglutide therapy. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Education, Health & Sport is the property of Nicolaus Copernicus University in Torun and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Education Research Complete
Description
Abstract:Introduction: Semaglutide (Ozempic) is a long-acting GLP-1 receptor agonist used in the treatment of type 2 diabetes and obesity. Its potent effects on appetite suppression, delayed gastric emptying, and weight reduction are well documented. Increasing scientific attention has focused on its potential influence on lean body mass and skeletal muscle, as emerging evidence suggests that semaglutide-induced weight loss may include clinically relevant reductions in muscle mass. Understanding the extent and significance of these changes is essential for safe long-term therapy. Material and Methods of Research: A literature review was conducted using PubMed, Google Scholar, and Scopus. Clinical trials, observational studies, meta-analyses, and relevant preclinical research published in English between 2018 and 2024 were analyzed. Results: Evidence indicates that semaglutide-induced weight loss consistently leads to reductions in lean mass, typically comprising 20–40% of total weight lost. Mechanisms include caloric deficit, reduced protein intake, appetite suppression, and changes in anabolic signalin. Several studies demonstrated preserved muscle strength or stabilization of lean mass when therapy was combined with adequate protein intake and resistance training. Preclinical findings suggest that part of the lean mass reduction is reversible after treatment discontinuation. Conclusion: Semaglutide affects muscle mass primarily indirectly through appetite suppression and significant weight reduction. While lean mass loss is common, functional muscle decline is not inevitable and may be mitigated through dietary optimization and structured physical activity. Regular monitoring of body composition should be considered during semaglutide therapy. [ABSTRACT FROM AUTHOR]
ISSN:23918306
DOI:10.12775/JEHS.2026.88.68182